Editor’s Note: Patient Worthy is honored to present this article, shared with us by our friends at the Seena Magowitz Foundation. When doctors diagnosed Michael
A major breakthrough for the 300 Irish patients living with butterfly skin. For the first time in Ireland, patients battling epidermolysis bullosa, a rare and
Editor’s Note: Patient Worthy is honored to share this story submitted to us by Regina Portnoy, a clinical researcher with over 20 years of experience.
Editor’s Note: Patient Worthy is honored to share this patient story from our friends at Elephants & Tea. To see the story in its original
As shared on drugs.com, Vascarta Inc. has reported encouraging results from a Phase 1b clinical study evaluating its investigational topical/transdermal curcumin gel, VAS-101, for the
Editor’s Note: Patient Worthy is honored to share this article from our friends at the Brighter Hope Foundation. To see the article in its original
Labcorp announced the nationwide availability of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer
As reported on drugs.com, Revolution Medicines has reported practice-changing efficacy results from a pivotal Phase 3 trial evaluating daraxonrasib in patients with metastatic pancreatic ductal
This, year the PCBers will meet in Indianapolis, Indiana. They will be celebrating 30 years as a community, as well as celebrating a much brighter
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the
As reported on Business Wire, Enveda, a clinical-stage biotechnology company focused on discovering novel small-molecule medicines, has reported encouraging results from a Phase 1b study
A recent article from Inside Precision Medicine states: For decades, systemic lupus erythematosus (SLE) has resisted tidy solutions, a shapeshifting autoimmune disease that crosses into
AstraZeneca has announced positive results from the pivotal phase III MIRANDA trial of tozorakimab, a groundbreaking first-in-class monoclonal antibody designed to treat Chronic Obstructive Pulmonary
On January 20, 2014, at 54 years old, I experienced what I casually called an “anxiety numbness event.” My left thumb and index finger went
The US Food and Drug Administration (FDA) has approved Idvynso, a groundbreaking two-drug single-tablet regimen combining 100 mg doravirine and 0.25 mg islatravir, for treating
My story began very suddenly on May 4th, 2025, when I was home from graduate school visiting my family. It had been a great day,
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults and remains one of the most difficult cancers to treat. Characterized by aggressive
WebMD published a story about a young woman, Maddie, who had spent nine years in wheelchair confinement resulting from a rare metabolic disease related to
Lung Cancer Research FoundationThe 2026 ASCO Annual Meeting in Chicago starts May 29, and we're eager to find out what #LungCancer developments everyone will be talking about! Join our June 17 Together Separately livestream to hear from the experts, who will recap the conference. Sign up at LCRF.org/ASCO2026
Lung Cancer Research FoundationWe’re proud to announce our Women & Lung Cancer video event with Dr. Isabel Preeshagul and Dr. Narjust Florez. This is a compilation of highlights from our webinars on women and lung cancer over the past five years. We invite you to watch – and to share it with anyone who might find it helpful. LCRF.org/women#video
#LungCancer #WLC #Women
Tom Seaman, Author at Patient Worthy
Tom Seaman, Author at Patient Worthy
patientworthy.com
Tom Seaman is a Certified Professional Life Coach in the area of health and wellness, and author of 2 books: Diagnosis Dystonia: Navigating the Journey and Beyond Pain and Suffering: Adapting to Adver...
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
